Amgen has entered an exclusive global license agreement with DISCO Pharmaceuticals to develop and commercialize therapeutic programs against a cancer cell surface target identified via DISCO’s proprietary surfaceome mapping platform. Under the deal terms, DISCO is eligible to receive up to $618 million in milestone payments plus royalties, reflecting the high potential value Amgen places on this genetically validated target. The collaboration will focus on bispecific antibody–drug conjugates and T-cell engagers with applications in small cell lung cancer and microsatellite-stable colorectal cancer, aligning with Amgen’s strategy to broaden its oncology pipeline with innovative, precision-targeted modalities.

On the latest trading day, Amgen shares declined by 2.12% even as the broader healthcare sector advanced on strong biotech earnings reports and favorable analyst upgrades. Investors cited profit-taking after recent gains and cautious outlook commentary from management, which tempered enthusiasm around near-term revenue growth. However, several brokerage firms maintained buy ratings, highlighting Amgen’s robust cash flow generation, its expanding dermatology and cardiovascular franchises, and the potential upside from the newly licensed DISCO asset.